News and Features
HHS Panel on Antiretroviral Guidelines for Adults and Adolescents Announces New Members
The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents (a working group of the Office of AIDS Research Council) is pleased to welcome 5 new scientific members to the Panel who will begin a 4-year term starting in March 2014.
- Thomas Giordano, MD, MPH (Baylor College of Medicine, Houston, TX)
- Richard Haubrich, MD (University of California San Diego, CA)
- Peter Hunt, MD (University of California San Francisco, CA)
- Marla Keller, MD (Albert Einstein College of Medicine, NY)
- Jeffrey Lennox, MD (Emory University, GA)
The Panel would like to express our gratitude and appreciation to the following outgoing scientific members for the many years of dedication and contributions in the development of these guidelines:
- Steven G. Deeks, MD (University of California San Francisco, CA)
- Carlos del Rio, MD (Emory University, GA)
- Joel Gallant, MD (Southwest CARE Center, NM)
- W. Keith Henry, MD (Hennepin County Medical Center & University of Minnesota, MN)
- Michael Saag, MD (University of Alabama at Birmingham, AL)
Corrections to the Pediatric Opportunistic Infections Guidelines
On December 11, 2013, the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children was updated to eliminate the dosing recommendation for anidulafungin for patients 18 years and older (found in the Candida Infections section and in Table 3: Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children—Summary of Recommendations). Users should reference the Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents for information on this patient population.
Recent HIV/AIDS News from NIAID, NIH, and FDA
- December 18, 2013: Animal Vaccine Study Yields Insights That May Advance HIV Vaccine Research
“A vaccine study in monkeys designed to identify measurable signs that the animals were protected from infection by SIV, the monkey version of HIV, as well as the mechanism of such protection has yielded numerous insights that may advance HIV vaccine research.”
Read the NIAID press release.
- December 17, 2013: NIH Names Leadership, Research Units for Restructured HIV/AIDS Clinical Trials Networks
“Principal investigators and clinical trials units (CTUs) have been chosen to lead and conduct the research of five HIV/AIDS clinical trials networks through 2021. The effort is directed and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.”
Read the NIH press release.
- December 13, 2013: Changes to Complera (Emtricitabine, Rilpivirine, Tenofovir Disoproxil Fumarate) Labeling
“On December 13, 2013, FDA approved changes to the Complera (emtricitabine, rilpivirine, tenofovir disoproxil fumarate) label to include the use of Complera for the treatment of HIV-1 infection in certain adult patients who are virologically suppressed on a stable ritonavir-boosted protease inhibitor regimen.”
Read the FDA announcement and view the AIDSinfo patient fact sheet on Complera.